

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Completed if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	Unassigned
Date Submitted: September 16, 2005			Filing Date	September 16, 2005
(use as many sheets as necessary)			First Named Inventor	Kenji SOEJIMA
			Group Art Unit	Unassigned
			Examiner Name	Unassigned
			Attorney Docket Number	081356-0247
Sheet	1	of	1	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1		JP 10-306705 A		President and Fellows of Harvard College	1/20/1990		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/MH/	A2	International Search Report of PCT/JP 2004/003802.	
/MH/	A3	B. PLAUMAER et al., "Epitope Mapping of Anti-ADAMTS-13 Antibodies in Patients with Acquired TTP", Blood, 11/16/2003, Vol. 102(II), p. 540a.	
/MH/	A4	B. PLAUMAER et al., "Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)" Blood, 11/15/2002, Vol. 100(10), pp. 3626-3632.	
/MH/	A5	HE. GERRITSEN et al., "Partial amino acid sequence of purified von Willebrand factor-cleaving protease", Blood, 9/15/2001, Vol. 98(6), pp. 1654-1661.	
/MH/	A6	CC HUANG et al., "Epitope mapping of factor VIII inhibitor antibodies of Chinese origin.", Br. J. Haematol., June 2001, Vol. 113(4), pp. 915-924.	
/MH/	A7	MA NARDI et al., "GP1IIa- (49-66) is a major pathaophysiologicaly relevant antigenic determinant for anti-platelet GP1IIa of HIV-1-related immunologic thrombocytopenia.", Proc. Natl. Acad. Sci. USA, July 8, 1997, Vol. 94(14), pp. 7589-7594.	
/MH/	A8	K. KOKAME et al., "Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity", Proc. Natl. Acad. Sci. USA, September 3, 2002, Vol. 99(18), pp. 11902-11907.	
/MH/	A9	S. CAL et al., "Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains.", Gene, January 23, 2002, Vol. 283 (1-2), pp. 49-62.	

Examiner Signature	/Maher Haddad/	Date Considered	01/03/2008
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/549,317
Date Submitted: September 21, 2006		Filing Date	3/17/2004
(use as many sheets as necessary)		First Named Inventor	Kenji SOEIJIMA
		Group Art Unit	1645
		Examiner Name	Unassigned
		Attorney Docket Number	081356-0247

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
/MH/	B1	EP	1 391 516	A1	JURIDICAL FOUNDATION, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE	2/25/2004		
/MH/	B2	EP	1 544 293	A1	JURIDICAL FOUNDATION, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE	6/22/2005		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/MH/	B3	Kenji SOEIJIMA et al., "A Noel Human Metalloprotease Synthesized in the Liver and Secreted into the Blood: Possibly the von Willebrand Factor- Cleaving Protease", J. Biochem. 130, 475-480, 2001.	
/MH/	B4	Kenji SOEIJIMA et al., "Analysis on the Molecular Species and Concentration of Circulating ADAMTS13 in Blood", J. BIOCHEM, 139, 147-154, 2006.	

Examiner Signature	/Maher Haddad/	Date Considered	01/03/2008
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 21, 2007 <i>(use as many sheets as necessary)</i>		Application Number	10/549,317
		Filing Date	3/17/2004
		First Named Inventor	Kenji SOEJIMA
		Art Unit	1644
		Examiner Name	Maher M. Haddad
Sheet 1 of 1	Attorney Docket Number	081356-0247	

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (If known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (If known)				

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
/MH/	C1	Xinglong ZHENG et al., "Structure of von Willebrand Factor-cleaving Protease (ADAMTS13), a Metalloprotease Involved in Thrombotic Thrombocytopenic Purpura", The Journal of Biological Chemistry, Vol. 276, No. 44, Issue of November 2, 2001, pp. 41059-41063.	

Examiner Signature	/Maher Haddad/	Date Considered	01/03/2008
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.